Favinil 200

Indications

Effective treatment for emerging or recurrent strains of pandemic influenza viruses, particularly when other antiviral medications prove ineffective or insufficiently potent.

Description

Favinil, approved for production and distribution in Japan as an influenza antiviral, is renowned for its selective inhibition of the RNA polymerase essential for viral replication within human host cells. Given its mechanism, which targets the RNA polymerase shared by both influenza and COVID-19, there’s optimism surrounding its potential efficacy against COVID-19.

Favinil is reserved for instances of novel or re-emerging influenza outbreaks where conventional antiviral treatments falter. Its availability is governed by Japan’s Health, Labor and Welfare Ministry, thus not yet accessible in markets or medical facilities, domestically or internationally.

Pharmacology

Favipiravir, a groundbreaking antiviral medication, is metabolized into favipiravir ribosyl triphosphate (favipiravir RTP), which specifically inhibits the RNA polymerase of the influenza virus, impeding its replication process. Unlike traditional influenza antivirals, Favinil showcases efficacy against various strains, including avian and swine viruses.

Dosage & Administration

For adults, the standard dosage entails oral administration of 1600 mg of Favipiravir twice daily on the initial day, followed by 600 mg orally twice daily from the second to the fifth day, or as directed by healthcare providers, with the entire treatment lasting for five days.

Interaction

Animal studies suggest potential adverse effects such as reduced red blood cell production and elevated liver function parameters. However, comprehensive toxicity data for Favinil in humans remains scarce.

Contraindications

Favipiravir is contraindicated for pregnant women or those planning pregnancy.

Side Effects

Common side effects include diarrhea and increased blood uric acid levels.

Pregnancy & Lactation

Favipiravir administration during pregnancy may lead to embryo developmental delays or fatality and is hence not recommended.

Precautions & Warnings

Favinil use warrants confirmation of non-pregnancy in women of childbearing age and diligent contraception throughout treatment and for seven days post-treatment. Special caution is advised for patients with hepatic or renal impairment, and usage should align with a registered physician’s guidance.

Use in Special Populations

While Favinil is an approved experimental drug, further studies are indispensable to assess its efficacy, potential toxic reactions, and suitability for pediatric use.

Overdose Effects

Animal studies indicate potential adverse effects, including decreased red blood cell production and liver abnormalities. However, comprehensive human toxicity data for Favinil are currently unavailable.

Therapeutic Class

Anti-viral drugs.

Storage Conditions

Store below 30°C, shielded from light and moisture, and out of children’s reach.